Summary of the Key Points in Plain Language
This article discusses a very counterintuitive phenomenon in the pharmaceutical industry: despite the domestic innovative drug sector seemingly emerging from a period of hardship in 2026, with Chinese pharmaceutical companies granting more new drug licenses to overseas giants and filing a record number of new clinical trials, the clinical CROs (contract research organizations that provide pharmaceutical research and development services) have fallen into the most intense price war in their history. Three years ago, companies were competing to undertake a Phase III cancer clinical trial for an fee of 80,000 yuan; now, some are willing to take on the same trial for 30,000 yuan. The gross profit margin of leading CROs has plummeted from 45% to 21%, and while the number of orders has increased, profits have decreased. This has led to a decline in the quality of services and the income of industry practitioners. The entire industry is desperately seeking a way out of this cycle of low-price competition.
---
Detailed Explanation of Each Point
1. **The Most Absurd Contradiction in the Industry: Upstream Is Reviving, but Downstream Service Providers Are Losing Profits**
Many might think that with more R&D orders from pharmaceutical companies, CROs should be making easy money. However, the reality is quite the opposite. The prices offered by CROs have dropped to absurd levels. Three years ago, a Phase III trial for non-small cell lung cancer with a team of 500 people typically cost 60-80 million yuan in services; now, a similar project can be won for just over 30 million yuan. Even top global CROs like IQVIA are seeing a decline in revenue per project in China.
This contradiction is a result of “pseudo-demand prosperity”: although pharmaceutical companies have more orders, they are still trying to save every penny after surviving the previous capital crunch. Many pharmaceutical companies have changed their bidding processes, eliminating half of the highest-bidding CROs in the first round and only considering those with relevant experience and quality systems. Price has become the sole criterion for entry, preventing higher-bidding companies from even competing. The majority of new orders are for common cancers and chronic diseases, which can be handled by hundreds of CROs, leading to fierce price competition and further pressure on prices.
2. **The Reality of Lowering Prices: “Not Taking Orders Means Dying Faster”**
Some may wonder why CROs would accept contracts that don’t even cover their labor costs. This is due to the industry’s nature. During the boom in biotech financing, starting a CRO was not much more difficult than opening a restaurant—a few experienced professionals and a rented office were enough. The profit came from the difference in the number of staff hired. However, this model has a fatal flaw: labor costs are fixed. Even if no projects are assigned, the monthly salaries and benefits for employees must be paid, and without orders, the company’s cash flow can be depleted quickly.
The industry is now in a dilemma: taking low-price contracts results in losses, while refusing orders means losing 100% of the staff’s salaries and potentially going bankrupt. It’s like drivers in the ride-hailing industry—accepting a 3-yuan order for a 2-kilometer ride means losing money on fuel; accepting it at all is better. As more companies choose this path, prices continue to drop.
3. **No Winners in the Price War: Everyone in the Chain Suffers**
Many think that price wars benefit pharmaceutical companies by saving money. In reality, no party benefits in the long run:
The most affected are the frontline workers, such as clinical coordinators in non-first-tier cities, who earn only 5,000 yuan per month. They are overwhelmed with multiple projects and have high turnover rates in top-tier hospitals. New employees often leave before understanding the projects properly. This leads to errors in data entry, missed patient follow-ups, and delayed submission of documents. Pharmaceutical companies save a few million in fees but may lose millions in delayed market launches, resulting in additional losses. CROs, in turn, struggle to pay their staff, creating a vicious cycle.
The price war also harms all parties in the chain. Small, unqualified companies can survive on low prices, preventing the elimination of inefficient firms, and the price war shows no sign of ending.
4. **CROs Seeking New Paths to Avoid Collapse**
Realizing that price wars are unsustainable, leading CROs are exploring three new approaches:
- Deep Integration with Pharmaceutical Companies: They are no longer charging by project but investing in pharmaceutical companies’ new drug projects, sharing sales profits or royalties from overseas licenses. This aligns their interests and eliminates the risk of price pressure.
- AI-Driven Transformation: AI replaces manual patient screening and data verification, significantly reducing recruitment time and costs. This approach allows CROs to focus on higher-value projects.
- High-Threshold Projects: CROs are targeting more complex tasks like cell and gene therapy or global multi-center trials, which require specialized skills and compliance. These projects are more profitable (3-6% higher margins) and are no longer competing with low-price contracts.
In essence, the current price war in clinical CROs reflects a broader trend in labor-intensive services: relying on cheap labor to make small profits will inevitably lead to competition deadlocks. Only by moving towards technology and higher barriers to entry can the industry escape the cycle of low-price competition.